Partial
Mixed Alignment
Patient Risk:
Moderate
Summary
Most safety/interaction and dosage-timing claims are consistent with the provided label (bile acid sequestrant spacing; liver enzyme elevations; myopathy/rhabdomyolysis; use with statins and note to refer for combination risks). However, multiple claims about grapefruit/CYP3A4 are not supported by the provided labeling excerpts, and several interaction/timing assertions are generalized beyond what the label text shown supports.
Category Scores
Accurate Statements
Bile-acid binding resins (e.g., cholestyramine or colestipol) can reduce ezetimibe absorption.
Label Drug Interactions (7): cholestyramine administration decreased the mean exposure of total ezetimibe; bile acid sequestrants timing instructions provided.
Clinicians usually separate dosing by several hours when bile-acid binding resins and ezetimibe are used together.
Label Dosage and Administration (2): administer ZETIA at least 2 hours before or 4 hours after administration of a bile acid sequestrant.
Ezetimibe can be associated with liver problems, including unusual fatigue, dark urine, right upper belly pain, and yellowing of the skin/eyes.
Label Warnings and Precautions (5.2): increases in serum transaminases; label also notes hepatobiliary disorders in post-marketing (e.g., hepatitis; elevations in liver transaminases). (The specific symptom list is not explicitly provided in the excerpts, but liver injury associations are supported.)
Ezetimibe can be associated with severe muscle pain or weakness.
Label Warnings and Precautions (5.3): myopathy (muscle pain, tenderness, or weakness associated with elevated CK).
The risk of severe muscle pain or weakness is especially a concern when ezetimibe is combined with a statin.
Label Warnings and Precautions (5.3): most rhabdomyolysis post-marketing reports were taking a statin or other agents associated with increased rhabdomyolysis risk; combination treatment risks referenced.
Unsupported Statements
Grapefruit inhibits CYP3A4 enzymes in the gut and liver.
No grapefruit/CYP3A4 information is included in the provided ZETIA label excerpts.
Ezetimibe is mainly processed in the gut and liver through pathways other than CYP3A4.
No CYP3A4-specific metabolism/processing statements for ezetimibe are included in the provided label excerpts.
Grapefruit is not generally known to cause a clinically important interaction with ezetimibe.
No grapefruit interaction guidance appears in the provided label excerpts.
Ezetimibe is commonly used with statins.
While the label indicates ezetimibe is used in combination with a statin, the claim that it is 'commonly used' is not supported by the provided label excerpts.
For most people taking ezetimibe, having grapefruit occasionally is unlikely to be a problem.
No grapefruit-related interaction risk characterization is provided in the provided label excerpts.
If extra caution is desired, grapefruit intake can be separated from ezetimibe dosing by a few hours.
The label provides timing instructions only for bile acid sequestrants, not grapefruit.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Any contraindication/precaution specifically tied to ezetimibe-hypersensitivity when relevant (e.g., hypersensitivity reactions) was not addressed in the response claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Safety is partially supported for bile acid sequestrant timing, liver enzyme elevations, and myopathy/rhabdomyolysis. However, grapefruit-related claims (including CYP3A4 inhibition and low likelihood of interaction) are unsupported by the provided label excerpts; this could mislead dosing/avoidance decisions if grapefruit interaction guidance were assumed from ZETIA labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mixed Alignment
Primary Issue
Unsupported grapefruit/CYP3A4 and grapefruit-risk claims not present in the provided ZETIA label excerpts.
Suggested Improvement
Remove or replace grapefruit-related statements with label-supported interaction/timing guidance (e.g., bile acid sequestrant spacing; note that combination risks should be referred to partner prescribing information).